biostudies-literatureUnknown12Petrocchi SInnovative Medicines Initiative<b>Background:</b> The potential value of patient preference studies has been recognized in clinical individual treatment decision-making between clinicians and patients, as well as in upstream drug decision-making. Drug developers, regulators, reimbursement and Health Technology Assessment (HTA) bodies are exploring how the use of patient preference studies could inform drug development, regulatory benefit risk-assessment and reimbursement decisions respectively. Understanding patient preferences may be especially valuable in decisions regarding Non-Small Cell Lung Cancer (NSCLC) treatment options, where a variety of treatment options with different characteristics raise uncertainty about which features are most important to NSCLC patients. As part of the Innovative Medicines Initiative PFrontiers in pharmacology602112https://www.ebi.ac.uk/biostudies/studies/S-EPMC7970036biostudies-literatureWhat Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences.PMC7970036Smith MYLouis EPravettoni GVandevelde MArnou ROliveri SPetrocchi SDurosini IJanssens RGalli Gde Marinis FNackaerts KHuys IGuiddi PGianoncelli LfalseWhat Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences.<b>Background:</b> The potential value of patient preference studies has been recognized in clinical individual treatment decision-making between clinicians and patients, as well as in upstream drug decision-making. Drug developers, regulators, reimbursement and Health Technology Assessment (HTA) bodies are exploring how the use of patient preference studies could inform drug development, regulatory benefit risk-assessment and reimbursement decisions respectively. Understanding patient preferences may be especially valuable in decisions regarding Non-Small Cell Lung Cancer (NSCLC) treatment options, where a variety of treatment options with different characteristics raise uncertainty about which features are most important to NSCLC patients. As part of the Innovative Medicines Initiative P2021-01-01T00:00:00Z20212025-04-04T22:00:37.921Z2025-04-04T22:00:37.921ZS-EPMC79700363374675010.3389/fphar.2021.602112